Fig. 1From: Plasma copeptin, kidney disease, and risk for cardiovascular morbidity and mortality in two cohorts of type 2 diabetesKaplan-Meier curves for the cumulative incidence of cardiovascular events during follow-up by tertiles of baseline plasma copeptin. a DIABHYCAR study; log-rank test Chi square = 15.9, p = 0.0004. b SURDIAGENE study; log-rank test Chi square = 78.4, p < 0.0001Back to article page